139
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications

, , , , , & show all
Pages 87-93 | Published online: 04 Sep 2018

References

  • TsochatzisEABoschJBurroughsAKLiver cirrhosisLancet201438399301749176124480518
  • Abd-ElsalamSSharaf-EldinMSolimanSEfficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practiceArch Virol20181631515628983675
  • AhmedOAKaisarHHHawashNEfficacy of sofosbuvir plus ribavirin with or without peginterferon-Alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infectionInfect Disord Drug Targets20171729510028413993
  • AhmedOAElsebaeyMAFouadMHAOutcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infectionInfect Drug Resist20181144144529628768
  • AhmedOAKaisarHHBadawiREfficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infectionInfect Drug Resist20181129529829535545
  • ZhouGWTaoZYPengCHLiHWReasonable choice of surgical procedures for patients with portal hypertensionHepatobiliary Pancreat Dis Int20032333033314599933
  • GroszmannRJAbraldesJGPortal hypertension: from bedside to benchJ Clin Gastroenterol2005394 Suppl 2S12515758647
  • D’AmicoGGarcia-TsaoGPagliaroLNatural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studiesJ Hepatol200644121723116298014
  • GuevaraMCárdenasAUrizJGinèsPPrognosis in patients with cirrhosis and ascitesGinèsPArroyoVRodésJSchrierRWAscites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis and TreatmentMaldenBlackwell2005260270
  • Sharaf-EldinMBediwyASKobtanAPigtail catheter: a less invasive option for pleural drainage in Egyptian patients with recurrent hepatic hydrothoraxGastroenterol Res Pract201620164013052401305527340399
  • ElfertAAbo AliLSolimanSIbrahimSAbd-ElsalamSRandomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitisEur J Gastroenterol Hepatol201628121450145427512927
  • RunyonBAIntroduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012Hepatology20135741651165323463403
  • BhogalHSanyalAJTreatment of refractory ascitesClin Liver Dis201323140142
  • WongFNadimMKKellumJAWorking Party proposal for a revised classification system of renal dysfunction in patients with cirrhosisGut201160570270921325171
  • HäussingerDKircheisGFischerRSchliessFvom DahlSHepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?J Hepatol20003261035103810898326
  • YeeHFLidofskySDAcute liver failure7th edFeldmanMFried-manLSSleisengerMHSleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, ManagementPhiladelphiaSaunders2002567574
  • KatanMMüllerBChrist-CrainMCopeptin: a new and promising diagnostic and prognostic markerCrit Care200812211711818355399
  • ChikanzaICPetrouPChrousosGPerturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implicationsAnn N Y Acad Sci200091782583411268412
  • MorgenthalerNGStruckJJochbergerSDünserMWCopeptin: clinical use of a new biomarkerTrends Endocrinol Metab2008192434918291667
  • AwayaHMitchellDGKamishimaTHollandGItoKMatsumotoTCirrhosis: modified caudate-right lobe ratioRadiology2002224376977412202712
  • AngeliPMerkelCPathogenesis and management of hepatorenal syndrome in patients with cirrhosisJ Hepatol200848Suppl 1S93S10318304678
  • SalernoFGerbesAGinèsPWongFArroyoVDiagnosis, prevention and treatment of hepatorenal syndrome in cirrhosisGut20075691310131817389705
  • CholongitasEPapatheodoridisGVVangeliMTerreniNPatchDBurroughsAKSystematic review: The model for end-stage liver disease–should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis?Aliment Pharmacol Ther20052211–121079108916305721
  • SolàEMoreiraRRodriguezE605 Plasma copeptin levels are increased in cirrhosis and correlate with hyponatremia and circulatory dysfunctionJ Hepatol201358S247S407
  • MorenoJPGrandclementEMonnetEPlasma copeptin, a possible prognostic marker in cirrhosisLiver Int201333684385123560938
  • KimerNGoetzeJPBendtsenFMøllerSNew vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory stateEur J Clin Invest201444544145224476551
  • BallSGVasopressin and disorders of water balance: the physiology and pathophysiology of vasopressinAnn Clin Biochem200744Pt 541743117761027
  • KimWRBigginsSWKremersWKHyponatremia and mortality among patients on the liver-transplant waiting listN Engl J Med2008359101018102618768945
  • CoenraadMJde RooijBJVerbruggenLvan HoekBvan der ReijdenJJVerspagetHW619 Copeptin; An independent prognostic factor in cirrhosis?J Hepatol2012562S245S246